Stoke Therapeutics appoints Ian Smith to Board of Directors

Stoke Therapeutics, Inc.

Ian Smith appointed as Class II director effective September 19, 2023.
He will receive an annual cash retainer of $40,000 and an initial stock option for 96,340 shares (~$305k fair value).
Smith brings over 20 years experience; served as EVP/COO/CFO at Vertex Pharmaceuticals.
He currently serves on boards of Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX), and others.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ian F. Smith

Class II director

STOK · Stoke Therapeutics, Inc.

Effective: 2023-09-19
Filed: September 20, 2023, 7:59 PM ET

elected Ian F. Smith, to serve on the Board as a Class II director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ian F. Smith was elected as Class II director at Stoke Therapeutics, Inc..

Action: elected
Role: Class II director

Exact text from the filing

elected Ian F. Smith, to serve on the Board as a Class II director, effective immediately.

View on SEC.gov

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-238627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.